Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Eli Lilly and Company
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial Effective Date | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |||||||||||||
Newly Registered Securities | ||||||||||||||||||||||||
Fees to Be Paid | Equity | Common Stock(1) | Rule 456(b) and Rule 457(r) (2) | (3)(4) | (3)(4) | (3)(4)(5) | (2) | (2) | ||||||||||||||||
| Equity | Preferred Stock(1) | Rule 456(b) and Rule 457(r) (2) | (3)(4) | (3)(4) | (3)(4)(5) | (2) | (2) | |||||||||||||||||
| Equity | Depositary Shares representing Preferred Stock(1) | Rule 456(b) and Rule 457(r) (2) | (3)(4) | (3)(4) | (3)(4)(5) | (2) | (2) | |||||||||||||||||
| Debt | Debt Securities(1) | Rule 456(b) and Rule 457(r) (2) | (3)(4) | (3)(4) | (3)(4)(5) | (2) | (2) | |||||||||||||||||
| Other | Warrants(1) | Rule 456(b) and Rule 457(r) (2) | (3)(4) | (3)(4) | (3)(4)(5) | (2) | (2) | |||||||||||||||||
| Other | Stock Purchase Contracts(1) | Rule 456(b) and Rule 457(r) (2) | (3)(4) | (3)(4) | (3)(4)(5) | (2) | (2) | |||||||||||||||||
| Other | Stock Purchase Units(1) | Rule 456(b) and Rule 457(r) (2) | (3)(4) | (3)(4) | (3)(4)(5) | (2) | (2) | |||||||||||||||||
Fees Previously Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||||||||||||
| Carry Forward Securities | ||||||||||||||||||||||||
Carry Forward Securities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||||||||||
| �� | ||||||||||||||||||||||||
| Total Offering Amounts | N/A | N/A | ||||||||||||||||||||||
| Total Fees Previously Paid | N/A | |||||||||||||||||||||||
| Total Fee Offsets | N/A | |||||||||||||||||||||||
| Net Fee Due | N/A | |||||||||||||||||||||||
| (1) | Separate consideration may or may not be received for securities that are issuable on exercise, conversion, settlement or exchange of other securities. |
| (2) | In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, Eli Lilly and Company (the “Registrant”) is deferring payment of all of the registration fee. Registration fees will be paid subsequently on a “pay as you go” basis. The Registrant will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee payment rate in effect on the date of such fee payment. |
| (3) | An indeterminate aggregate initial offering price and number or amount of the securities of each identified class is being registered as may from time to time be issued at indeterminate prices, including securities that may be issued upon exercise, conversion, settlement or exchange of, any securities offered hereunder. |
| (4) | Not specified as to each class of securities to be registered, pursuant to General Instruction II.E. of Form S-3. |
| (5) | Exclusive of accrued interest and accumulated dividends, if any. |